SCHEMBL4893004

SCHEMBL4893004

C=CCN(N)C(=O)OCc1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HCAR2 Q8TDS4 1/20 0.49
ALDH1A1 P00352 5/20 0.46
TDP1 Q9NUW8 2/20 0.45
MAPK1 P28482 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
SLC6A2 P23975 1/20 0.45
SLC6A3 Q01959 1/20 0.45
KMT2A Q03164 1/20 0.45
LMNA P02545 2/20 0.43
CCR6 P51684 1/20 0.42
PAX8 Q06710 1/20 0.42
TGM2 P21980 1/20 0.42
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA9 Q16790 1/20 0.41
SIGMAR1 Q99720 1/20 0.40
MAPT P10636 1/20 0.40
HPGD P15428 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1926539 0.86 ALDH1A1 (0.47) HCAR2ALDH1A1TDP1MAPK1L3MBTL1
SCHEMBL541750 0.84 HCAR2 (0.51) HCAR2ALDH1A1TDP1MAPK1L3MBTL1
SCHEMBL8651697 0.83 HCAR2 (0.50) HCAR2ALDH1A1TDP1MAPK1L3MBTL1
SCHEMBL13684203 0.81 ALDH1A1 (0.50) HCAR2ALDH1A1TDP1MAPK1L3MBTL1
SCHEMBL8101654 0.81 HCAR2 (0.49) HCAR2ALDH1A1TDP1MAPK1L3MBTL1
SCHEMBL7152866 0.80 ALDH1A1 (0.52) HCAR2ALDH1A1TDP1MAPK1L3MBTL1
SCHEMBL4690235 0.80 HCAR2 (0.47) HCAR2ALDH1A1TDP1MAPK1L3MBTL1
SCHEMBL3081849 0.80 HCAR2 (0.47) HCAR2ALDH1A1TDP1MAPK1L3MBTL1
SCHEMBL1517791 0.79 HCAR2 (0.46) HCAR2ALDH1A1TDP1MAPK1L3MBTL1
SCHEMBL21573938 0.79 ALDH1A1 (0.47) HCAR2ALDH1A1TDP1MAPK1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7470703-B1 Yohimbine derivatives and use thereof THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2008-12-30 US disclosed
US-6444829-B1 (2S,4R)-4-MERCAPTO-1-(NAPHTHALENE-2-SULFONYL)-PYRROLIDINE-2 -CARBOXYLIC ACID N'-ISOBUTYL-N'-(4-METHYL-BENZENESULFONYL)-HYDRAZIDE, FOR EXAMPLE; INHIBITORS OF METALLOPROTEASES, E.G. ZINC PROTEASES; VASODILATORS HOFFMANN-LA ROCHE INC. 2002-09-03 US disclosed
US-20020040048-A1 PYRROLIDINE COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2002-04-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020040048-A1 PYRROLIDINE COMPOUNDS PREP, PEPD, MMP3 HCAR2 725/4885ALDH1A1 684/4885TDP1 820/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.